Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SANGAMO THERAPEUTICS, INCSGMO · Entity 7038 | EVP, Technical Operations | May 25, 2023 | May 30, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SANGAMO THERAPEUTICS, INC
Report date May 25, 2023 · Filed May 30, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 171,467 |
Reported balance
After 2023-05-25 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-05-25 · Tax withholding · Disposed 1,750 · Balance 171,467 F1: Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on May 25, 2023, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on May 25, 2023 of $1.33/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F2: Includes: (a) 3,312 shares resulting from the May 25, 2023 vesting installment of the Reporting Person's February 25, 2022 RSU grant, and the remaining 35,438 shares will vest in successive equal quarterly installments through February 25, 2025, (b) 13,336 shares subject to the Reporting Person's February 25, 2021 RSU grant that will vest in one final installment on February 25, 2024 and (c) 45,000 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on May 25, 2023, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on May 25, 2023 of $1.33/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise.
F2: Includes: (a) 3,312 shares resulting from the May 25, 2023 vesting installment of the Reporting Person's February 25, 2022 RSU grant, and the remaining 35,438 shares will vest in successive equal quarterly installments through February 25, 2025, (b) 13,336 shares subject to the Reporting Person's February 25, 2021 RSU grant that will vest in one final installment on February 25, 2024 and (c) 45,000 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 25, 2023 Filed May 30, 2023 20:44 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 1,750 | $1.33 | $2,327.50 |
DisclosureSEC source: 0001209191-23-032912 · doc4.xml · nonDerivative · entry 1 Ramelmeier Rolf Andrew · CIK 0001789340 · EVP, Technical Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 171,467 F1 · shares: Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on May 25, 2023, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on May 25, 2023 of $1.33/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F2 · balance_after: Includes: (a) 3,312 shares resulting from the May 25, 2023 vesting installment of the Reporting Person's February 25, 2022 RSU grant, and the remaining 35,438 shares will vest in successive equal quarterly installments through February 25, 2025, (b) 13,336 shares subject to the Reporting Person's February 25, 2021 RSU grant that will vest in one final installment on February 25, 2024 and (c) 45,000 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| February 25, 2023 Filed Mar 6, 2023 22:09 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 15,618 | $2.66 | $41,543.88 |
DisclosureSEC source: 0001209191-23-016397 · doc4.xml · nonDerivative · entry 2 Ramelmeier Rolf Andrew · CIK 0001789340 · EVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,217 F3 · shares: Represents shares underlying the portions of RSU grants that vested on February 25, 2023, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on February 24, 2023 of $2.66/share, pursuant to the terms of the 2018 EIP. This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F2 · balance_after: Includes 690 shares acquired on May 31, 2022 and 716 shares acquired on November 30, 2022 under the Issuer's 2020 Employee Stock Purchase Plan. F4 · balance_after: Includes: (a) 11,997 shares resulting from the February 25, 2023 final vesting installment of the Reporting Person's February 25, 2020 RSU grant, (b) 8,722 shares resulting from the February 25, 2023 vesting installment of the Reporting Person's February 25, 2021 RSU grant and 13,336 shares subject to such RSU grant that will vest in one final installment on February 25, 2024 and (c) 8,832 shares resulting from the February 25, 2023 vesting installment of the Reporting Person's February 25, 2022 RSU grant, and the remaining 40,500 shares will vest in 8 successive equal quarterly installments. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| February 24, 2023 Filed Mar 6, 2023 22:09 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantStock Option (Right to Buy) · Derivative | 210,000 | $0.00 Strike: $2.66 | $0.00 |
DisclosureSEC source: 0001209191-23-016397 · doc4.xml · derivative · entry 3 Ramelmeier Rolf Andrew · CIK 0001789340 · EVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,000 Underlying: Common Stock · 210,000 shares Expires 2033-02-23 F5 · derivative.exercise_date: One-quarter (1/4) of the shares subject to the option will vest and become exercisable on the first anniversary of the grant date, and the remainder of the shares will vest and become exercisable in 24 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| February 24, 2023 Filed Mar 6, 2023 22:09 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantCommon Stock | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016397 · doc4.xml · nonDerivative · entry 1 Ramelmeier Rolf Andrew · CIK 0001789340 · EVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,835 F1 · shares: Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through each such date and subject to acceleration as provided in the 2018 EIP. F2 · balance_after: Includes 690 shares acquired on May 31, 2022 and 716 shares acquired on November 30, 2022 under the Issuer's 2020 Employee Stock Purchase Plan. Read SEC document |
| February 25, 2022 Filed Mar 1, 2022 22:19 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantStock Option (Right to Buy) · Derivative | 145,800 | $0.00 Strike: $5.90 | $0.00 |
DisclosureSEC source: 0001209191-22-014173 · doc4.xml · derivative · entry 3 Ramelmeier Rolf Andrew · CIK 0001789340 · EVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,800 Underlying: Common Stock · 145,800 shares Expires 2032-02-24 F5 · derivative.exercise_date: One-quarter (1/4) of the shares subject to the option will vest and become exercisable on the first anniversary of the grant date, and the remainder of the shares will vest and become exercisable in 24 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| February 25, 2022 Filed Mar 1, 2022 22:19 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantCommon Stock | 54,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-014173 · doc4.xml · nonDerivative · entry 2 Ramelmeier Rolf Andrew · CIK 0001789340 · EVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,429 F4 · shares: Represents shares of common stock issuable upon settlement of an RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| February 25, 2022 Filed Mar 1, 2022 22:19 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 12,388 | $5.90 | $73,089.20 |
DisclosureSEC source: 0001209191-22-014173 · doc4.xml · nonDerivative · entry 1 Ramelmeier Rolf Andrew · CIK 0001789340 · EVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,429 F1 · shares: Represents shares underlying the portions of restricted stock unit ("RSU") grants that vested on February 25, 2022 which were surrendered by the Reporting Person to the Issuer for tax withholding using the Issuer's closing stock price on February 25, 2022 of $5.90/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). F2 · balance_after: Includes: (a) 2,727 shares resulting from the February 25, 2022 final vesting installment of the Reporting Person's February 25, 2019 RSU grant, (b) 11,993 shares resulting from the February 25, 2022 vesting of the Reporting Person's February 25, 2020 RSU grant and 18,337 shares subject to such RSU grant that will vest in one final annual installment on February 25, 2023, and (c) 8,722 shares resulting from the February 25, 2022 vesting of the Reporting Person's February 25, 2021 RSU grant and 26,668 shares subject to such RSU grant that will vest in two remaining annual installments of 13,332 shares and 13,336 shares on February 25, 2023 and 2024, respectively. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. F3 · balance_after: Includes 2,000 shares acquired on April 30, 2021 and 346 shares acquired on October 29, 2021 under the Issuer's 2010 Employee Stock Purchase Plan and 272 shares acquired on May 8, 2021 under the Issuer's 2020 Employee Stock Purchase Plan. Read SEC document |
| February 25, 2021 Filed Mar 2, 2021 02:11 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantStock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $11.19 | $0.00 |
DisclosureSEC source: 0001209191-21-015522 · doc4.xml · derivative · entry 3 Ramelmeier Rolf Andrew · CIK 0001789340 · EVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2031-02-24 F4 · derivative.exercise_date: One-quarter (1/4) of the option shares vest and become exercisable upon completion of one (1) year of Continuous Service, as defined in the 2018 EIP, as amended, by the Reporting Person measured from the February 25, 2021 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, subject to the Reporting Person's Continuous Service as defined in the 2018 EIP, as amended, through each such vesting date, and subject to acceleration as provided in the 2018 EIP, as amended. Read SEC document |
| February 25, 2021 Filed Mar 2, 2021 02:11 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-015522 · doc4.xml · nonDerivative · entry 2 Ramelmeier Rolf Andrew · CIK 0001789340 · EVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,199 F3 · shares: Represents 40,000 shares of common stock issuable upon settlement of RSUs granted to the Reporting Person on February 25, 2021 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's Continuous Service as defined in the 2018 EIP, as amended, through such dates and subject to acceleration as defined in the 2018 EIP, as amended. Read SEC document |
| February 25, 2021 Filed Mar 2, 2021 02:11 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 7,779 | $11.19 | $87,047.01 |
DisclosureSEC source: 0001209191-21-015522 · doc4.xml · nonDerivative · entry 1 Ramelmeier Rolf Andrew · CIK 0001789340 · EVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,199 F1 · shares: Represents shares underlying the portions of restricted stock units ("RSUs") that vested on February 25, 2021 which were surrendered by the Reporting Person to the Issuer for tax withholding, using the Issuer's closing stock price on February 25, 2021 of $11.19/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP, as amended"). F2 · balance_after: Includes: (a) 2,726 shares resulting from the February 25, 2021 vesting of the Reporting Person's February 25, 2019 RSU grant and 4,167 shares subject to such RSU grant that will vest in one final annual installment on February 25, 2022; and (b) 11,993 shares resulting from the February 25, 2021 vesting of the Reporting Person's February 25, 2020 RSU grant and 36,668 shares subject to such RSU grant that will vest in two remaining annual installments of 18,331 shares and 18,337 shares on February 25, 2022 and 2023 respectively. The vesting of all such RSUs is subject to the Reporting Person's continued service as defined in the 2018 EIP, as amended, through such dates and subject to acceleration as defined in the 2018 EIP, as amended. Read SEC document |
| December 31, 2020 Filed Jan 6, 2021 21:27 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | SaleCommon Stock | 2,464 | $16.74 | $41,247.36 |
DisclosureSEC source: 0001209191-21-002078 · doc4.xml · nonDerivative · entry 1 Ramelmeier Rolf Andrew · CIK 0001789340 · EVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,978 F1 · balance_after: Included in this total are: (a) 8,333 shares from the Reporting Person's February 25, 2019 restricted stock unit (RSU) grant that will vest in two remaining annual installments on February 25, 2021 and February 25, 2022, resulting in such RSU grant being vested in full on the third (3rd) anniversary of the grant date; and (b) 55,000 shares from the Reporting Person's February 25, 2020 RSU grant that will vest in three annual installments on February 25, 2021, February 25, 2022 and February 25, 2023, resulting in such RSU grant being vested in full on the third (3rd) anniversary of the grant date. F2 · balance_after: All such RSUs are granted pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP, as amended") and vested or will vest with respect to 1/3rd of the shares in each respective RSU grant in three equal annual installments over the three-year period measured from the dates of grant, subject to the Reporting Person's Continuous Service as defined in the 2018 EIP, as amended, through such dates and subject to acceleration as defined in the 2018 EIP, as amended. Read SEC document |
| December 24, 2020 Filed Dec 31, 2020 00:51 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | SaleCommon Stock | 3,331 | $18.13 | $60,391.03 |
DisclosureSEC source: 0001209191-20-065591 · doc4.xml · nonDerivative · entry 1 Ramelmeier Rolf Andrew · CIK 0001789340 · EVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,442 F1 · balance_after: Includes: (a) 2,000 shares acquired by the Reporting Person on April 30, 2020; and (b) 645 shares acquired by the Reporting Person on October 30, 2020 under the Issuer's 2010 Employee Stock Purchase Plan, as amended. F2 · balance_after: Also included in this total are: (a) 8,333 shares from the Reporting Person's February 25, 2019 restricted stock unit (RSU) grant that will vest in two remaining annual installments on February 25, 2021 and February 25, 2022, resulting in such RSU grant being vested in full on the third (3rd) anniversary of the grant date; and (b) 55,000 shares from the Reporting Person's February 25, 2020 RSU grant that will vest in three annual installments on February 25, 2021, February 25, 2022 and February 25, 2023, resulting in such RSU grant being vested in full on the third (3rd) anniversary of the grant date. F3 · balance_after: All such RSUs are granted pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP, as amended") and vested or will vest with respect to 1/3rd of the shares in each respective RSU grant in three equal annual installments over the three-year period measured from the dates of grant, subject to the Reporting Person's Continuous Service as defined in the 2018 EIP, as amended, through such dates and subject to acceleration as defined in the 2018 EIP, as amended. Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 00:33 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantStock Option (Right-to-Buy) · Derivative | 110,000 | $0.00 Strike: $6.80 | $0.00 |
DisclosureSEC source: 0001209191-20-013232 · doc4.xml · derivative · entry 3 Ramelmeier Rolf Andrew · CIK 0001789340 · EVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 110,000 shares Expires 2030-02-24 F4 · derivative.exercise_date: One-quarter (1/4) of the option shares vest and become exercisable upon completion of one (1) year of service by the Reporting Person measured from the February 25, 2020 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date. Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 00:33 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantCommon Stock | 55,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-013232 · doc4.xml · nonDerivative · entry 2 Ramelmeier Rolf Andrew · CIK 0001789340 · EVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,128 F3 · shares: Represents 55,000 shares subject to restricted stock units granted on February 25, 2020 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such dates. Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 00:33 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 1,703 | $6.80 | $11,580.40 |
DisclosureSEC source: 0001209191-20-013232 · doc4.xml · nonDerivative · entry 1 Ramelmeier Rolf Andrew · CIK 0001789340 · EVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,128 F1 · shares: Represents shares underlying the portion of the Restricted Stock Unit that vested on February 25, 2020 surrendered by the Reporting Person to the Issuer for tax withholding, using the Issuer's closing stock price on February 25, 2020 of $6.80/share, pursuant to the terms of the Issuer's 2018 Equity Incentive Plan. F2 · balance_after: Includes 61 shares acquired by the Reporting Person on October 31, 2019 under the Issuer's 2010 Employee Stock Purchase Plan, as amended. Also included in this total are 2,464 shares resulting from the February 25, 2020 vesting of Reporting Person's February 25, 2019 restricted stock unit grant and 8,333 shares subject to such restricted stock unit grant that will vest in two remaining annual installments on February 25, 2021 and February 25, 2022, resulting in such restricted stock unit grant being vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.